Description
Olmesartan medoxomil is an angiotensin II type 1 receptor (AT1) inhibitor that inhibits negative regulatory feedback on renin secretion, decreasing secretion of aldosterone and resulting in decreased peripheral vascular resistance (vasodilation). This compound exhibits antihypertensive, cardioprotective, vasodilatory, and anti-inflammatory activities. Due to this action, olmesartan increases cerebral blood flow and cerebrovascular reserve capacity in hypertensive stroke patients. Additionally, this compound improves cardiac function through activation of the DLL4/Notch1 signaling pathway in animal models of chronic cardiac pressure overload. Olmesartan also inhibits activation of apoptosis signal regulating kinase 1 (ASK1) in animal models of diabetes, attenuating cardiac inflammation and vascular endothelial dysfunction.
References
You J, Wu J, Jiang G, et al. Olmesartan attenuates cardiac remodeling through DLL4/Notch1 pathway activation in pressure overload mice. J Cardiovasc Pharmacol. 2013 Feb;61(2):142-51. PMID: 23188126.
Verdecchia P, Angeli F, Repaci S, et al. Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag. 2009;5:939-48. PMID: 19997575.
Matsumoto S, Shimodozono M, Miyata R, et al. Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke. Hypertens Res. 2009 Nov;32(11):1015-21. PMID: 19745828.
Yamamoto E, Dong YF, Kataoka K, et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension. 2008 Sep;52(3):573-80. PMID: 18678790.
Brousil JA, Burke JM. Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther. 2003 Apr;25(4):1041-55. PMID: 12809956.
